American Urological Association Annual Meeting | Conference

Darolutamide Associated With Lower Rates of Treatment Discontinuation and Disease Progression in nmCRPC

April 29th 2023

Treatment with darolutamide was associated with lower rates of discontinuation and progression to metastatic disease compared with enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

Long-Term JAVELIN Bladder 100 Data Support Avelumab Maintenance in Advanced Urothelial Carcinoma

April 28th 2023

First-line avelumab maintenance therapy prolonged survival in patients with advanced urothelial carcinoma, regardless of response to first-line chemotherapy, according to findings from an exploratory subgroup analysis of the phase 3 JAVELIN Bladder 100 trial.

68Ga-FAP-2286 PET Imaging Influences Bladder Cancer Treatment Decisions

April 28th 2023

The use of 68Ga-FAP-2286 PET imaging may improve treatment selection and response assessment in patients with bladder cancer, according to findings from a pilot study evaluating the diagnostic performance of this imaging technology.

Dr Basin on Pharmacological Inhibition of Hsp70 in Belzutifan-Resistant RCC

April 28th 2023

Michael Basin, MD, discusses how the pharmacological inhibition of the molecular chaperone Hsp70 overcomes belzutifan resistance in clear cell renal cell carcinoma.

Dr Katims on the Utility of the MSK-ACCESS Assay in Node+ MIBC

April 28th 2023

Andrew Katims, MD, MPH, discusses the utility of a circulating tumor DNA assay (MSK-ACCESS) in patients with node-positive muscle-invasive bladder cancer.

Frontline Olaparib Plus Abiraterone Reduces PSA Levels, Delays Time to PSA Progression in mCRPC

April 28th 2023

The addition of olaparib to abiraterone acetate resulted in numerically higher prostate-specific antigen response rates and prolonged time to PSA progression vs abiraterone alone when used in the frontline treatment of patients with metastatic castration-resistant prostate cancer.

Extended Darolutamide Demonstrates Long-term Safety, Clinical Benefit in Nonmetastatic CRPC

April 28th 2023

Darolutamide given in an extended duration was linked with long-term clinical benefit and safety in patients with nonmetastatic castration-resistant prostate cancer.

Apalutamide Dose Reduction Does Not Significantly Reduce Skin-related AEs in Advanced Prostate Cancer

April 28th 2023

Reduced doses of apalutamide did not significantly decrease rates of skin-related adverse effects vs full-dose apalutamide in patients with advanced prostate cancer.

177Lu-PSMA-I&T Generates PSA Responses With Tolerable Safety in mCRPC

April 28th 2023

Treatment with lutetium 177 PSMA-I&T radioligand therapy led to prostate-specific antigen declines with an acceptable toxicity profile in patients with metastatic castration-resistant prostate cancer.

Zoledronic Acid Lowers Risk of Fracture in mHSPC

April 28th 2023

The use of zoledronic acid or other bisphosphonates was associated with a significant reduction in risk of fracture in patients with metastatic hormone-sensitive prostate cancer.

Tislelizumab Plus Nab-Paclitaxel Yields Preliminary Efficacy in NMBIC

May 18th 2022

The combination of tislelizumab plus nab-paclitaxel demonstrated benefit and a tolerable safety profile in patients with high-risk non–muscle invasive bladder cancer.

Sabizabulin Yields Encouraging rPFS, Tolerable Toxicity Profile in Previously Treated mCRPC

May 17th 2022

The utilization of sabizabulin in patients with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting therapy yielded significant and durable objective tumor responses, according to results of a phase 1b/2 trial (NCT03752099).

Immunotherapy Plus Nadofaragene Firadenovec Could Display Synergistic Activity in NMIBC

May 17th 2022

Nadofaragene firadenovec combined with immune checkpoint inhibitors such as pembrolizumab may play a synergistic role in the treatment of patients with Bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer.

Antegrade Administration of Mitomycin Gel Provides Safe, Effective Approach in Upper Tract Urothelial Carcinoma

May 16th 2022

Data from a retrospective analysis demonstrated that mitomycin gel was safe and effective when administered using an antegrade approach in real-world populations of patients with low-grade upper tract urothelial cancer.

Neoadjuvant Tislelizumab/Nab-Paclitaxel Combo Produces Early Activity in MIBC

May 16th 2022

The combination of neoadjuvant tislelizumab and nab-paclitaxel elicited a high rate of pathologic complete response in patients with muscle-invasive bladder cancer, according to preliminary findings from the phase 2 TRUCE-01 trial.

Dr. Ghali on Nectin-4 and TROP-2 Expression in Urothelial, Variant Histology Bladder Cancer

May 16th 2022

Fady Ghali, MD, discusses the expression of Nectin-4 and TROP-2 in variant histology bladder cancer and urothelial cancer.

Dr. Nguyen on the Efficacy of IS-002 for Robotic Prostatectomy in Prostate Cancer

May 16th 2022

Hao G. Nguyen MD, PhD, discusses the efficacy and safety of IS-002, a prostate-specific membrane antigen–targeting fluorophore, for image-guided surgery in patients with prostate cancer undergoing robotic prostatectomy.

Precision Medicine in Oncology®: TROP-2, Nectin-4 Are Highly Expressed in Urothelial, Variant Histology Bladder Cancer

May 16th 2022

TROP-2 and Nectin-4, surface cell targets of sacituzumab govitecan and enfortumab vedotin, respectively, are highly expressed in urothelial cancer and variant histology bladder cancer.

Infigratinib Generates Activity in FGFR-Mutated Urothelial Carcinoma

May 16th 2022

Infigratinib yielded notable activity and tolerability in patients with localized upper tract urothelial carcinoma harboring FGFR1/2/3 mutations.

IS-002 Improves Prostate Cancer Visualization Prior to Robotic Prostatectomy

May 16th 2022

The novel, near-infrared, prostate-specific membrane antigen-targeted fluorophore IS-002 was safe, well-tolerated, and allowed for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy.